There was a short update on the ZonMw ME/CFS program. Sjaak de Gouw will be the new chair of the program.
https://www.zonmw.nl/nl/nieuws/mecv...uwe-richtlijn-mecvs-en-1e-projecten-van-start
Nico Drost (€4.4 million to compensate for the subsidy wrongly awarded to ME/CFS Lines by ZonMw from the budget of the ME/CFS Research Program): accepted!
Interesting. A caveat would be though whether the Lifelines cohort identifies ME/CFS accurately or not, and I believe there are doubts about that.During the ZonMw conference on the Dutch ME/CFS research program yesterday, one researcher said that they estimated the heritability of ME/CFS in the Lifelines cohort at 43% [34-51] - findings that are still to be published.
During the ZonMw conference on the Dutch ME/CFS research program yesterday, one researcher said that they estimated the heritability of ME/CFS in the Lifelines cohort at 43% [34-51] - findings that are still to be published.
I think you've erroneously repeated 'ME/CFS' here. Should it be something else?Another researcher, Cindy Boer said that she is leading a new major collaboration: ‘Genetic epidemiology of ME/CFS’ that has 30.000 people with ME/CFS and several hundred thousand with ME/CFS.
Apologies, the last one should have been 'without ME/CFS'.I think you've erroneously repeated 'ME/CFS' here. Should it be something else?
During the ZonMw conference on the Dutch ME/CFS research program yesterday, one researcher said that they estimated the heritability of ME/CFS in the Lifelines cohort at 43% [34-51] - findings that are still to be published.
This is good news, and exactly what we need. With GWAS studies, size makes a big difference, and it’s fairly easy to combine the results of different studies to get more robust results. Separately, it’s also important to validate/replicate findings from one study in a separate, independent cohort.Another researcher, Cindy Boer said that she is leading a new major collaboration: ‘Genetic epidemiology of ME/CFS’ that has 30.000 people with ME/CFS and several hundred thousand without ME/CFS.
When someone asked if their study is not too similar to DecodeME she responded that there have been talks talked with the DecodeME team but that higher sample sizes around 40.000 will be needed and that therefore collaboration is necessary. She also said it is important to validate the results that will come out of DecodeME in other cohorts.
That is very high, and as @Jonathan Edwards says, if it were this high, you’d expect some genetic findings by now.During the ZonMw conference on the Dutch ME/CFS research program yesterday, one researcher said that they estimated the heritability of ME/CFS in the Lifelines cohort at 43% [34-51] - findings that are still to be published.
So presumably they are doing another genome screen like DecodeME, but yes, the question is where the genetic component calculation comes from.
I thin there may have been a twin analysis in the US from a huge cohort about five years back but I heard no more about that and it seemed that the definition of the cohort might be pretty loose.
Dibble et al said:An analysis of US health insurance claimed a high narrow-sense heritability (ℎ2=0.48) of CFS, , whereas an analysis of the UK Biobank individuals self-reporting a CFS diagnosis reported a less striking heritability (single nucleotide polymorphism- [SNP-] based approximate h2 = 0.08 with low confidence) (http://www.nealelab.is/uk-biobank). The third, a large twin-based study of CFS-like cases, produced an inconclusive result, with the 95% confidence interval of h2 including zero [0.03 (0.00–0.65)] (25).
From what I understood, the lifelines estimate was based on how prevalent ME/CFS was among relatives of ME/CFS patients.maybe it's just based on a correlation between parents and offspring.
I remember a large US insurance study from a few years back - not sure if it wsa this one - but it had a low sex ratio and CFS incidence was highest in the over 60s, making that study look suspect.They report quite a range of heritability results - I'm not sure how they're calculated but the large estimate from the US insurance data is surely not a twin study, maybe it's just based on a correlation between parents and offspring. Maybe you would expect some degree of confounding from lifestyle that could lead to a higher estimate? Would be good to look at these studies a bit closer.
Interesting. A caveat would be though whether the Lifelines cohort identifies ME/CFS accurately or not, and I believe there are doubts about that.
Yes i.e. you'd need to see the methodology.The Lifelines ME/CFS cohort was based on Fukuda criteria, (Rosmalen) in Groningen. Patients got reimbursed for the 4.4 million by the government. New database in line with Decode ME, with that 4.4 million budget.